The DOI matches its Crossref record; 37 of the 43 references it cites were found in a registry or an index.
Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors
Open accessPublished version of a preprint
Abstract
Purpose: Genetic alterations of KRAS, CDKN2A, TP53, and SMAD4 are the most frequent events in pancreatic cancer. We determined the extent to which these 4 alterations are coexistent in the same carcinoma, and their impact on patient outcome. Experimental Design: Pancreatic cancer patients who underwent an autopsy were studied (n = 79). Matched primary and metastasis tissues were evaluated for intragenic mutations in KRAS, CDKN2A, and TP53 and immunolabeled for CDKN2A, TP53, and SMAD4 protein products. The number of altered driver genes in each carcinoma was correlated to clinicopathologic features. Kaplan–Meier estimates were used to determine median disease free and overall survival, and a Cox proportional hazards model used to compare risk factors. Results: The number of genetically altered driver genes in a carcinoma was variable, with only 29 patients (37%) having an alteration in all 4 genes analyzed. The number of altered driver genes was significantly correlated with disease free survival (P = 0.008), overall survival (P = 0.041), and metastatic burden at autopsy (P = 0.002). On multivariate analysis, the number of driver gene alterations in a pancreatic carcinoma remained independently associated with overall survival (P = 0.046). Carcinomas with only 1 to 2 driver alterations were enriched for those patients with the longest survival (median 23 months, range 1 to 53). Conclusions: Determinations of the status of the 4 major driver genes in pancreatic cancer, and specifically the extent to which they are coexistent in an individual patients cancer, provides distinct information regarding disease progression and survival that is independent of clinical stage and treatment status. Clin Cancer Res; 18(22); 6339–47. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Coexistent alterations in CDKN2A, KRAS, TP53 and SMAD4 were observed in pancreatic cancer, with frequent loss of tumor suppressors like CDKN2A, ARID1A, APC and ID3 [26,44].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genetic analysis indicates complex interactions among KRAS, CDKN2A, TP53 and SMAD4 alterations, influencing metastatic burden and survival [26].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Self-citationDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Self-citationMassive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Self-citationHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Self-citationCaldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M. E. M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,132
Self-citationIacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081
Self-citationAguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 4×
“Furthermore, although genetically engineeredmousemodels indicate that the concomitant expression of thesemutated genes is crucial to progress to invasion and metastasis in PDACs (15–19), the extent to which the coexistence of 3 or more of these altered genes in the same PDAC influence thebiologic behavior and survival…”
BackgroundInfluentialProgression model for pancreatic cancer.
Hruban, R. H., Goggins, M., Parsons, J., & Kern, S. E. (2000) · PubMed · Cited by 872
Self-citationBardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development · doi:10.1101/gad.1478706 · Cited by 674
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Schutte, M. E. M., Hruban, R. H., Geradts, J., Maynard, R. D., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte‐Waldhoff, I., Schmiegel, W., et al. (1997) · PubMed · Cited by 659
Self-citationYachida, S., Vakiani, E., White, C. M., Zhong, Y., Saunders, T., Morgan, R., de Wilde, R. F., Maitra, A., Hicks, J. L., Marzo, A. M. D., et al. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182417d36 · Cited by 542
Self-citationSjögren, S., Inganäs, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., & Bergh, J. C. S. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.173 · Cited by 381
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Eshleman, J. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0227 · Cited by 371
Self-citationWilentz, R. E., Geradts, J., Maynard, R. D., Offerhaus, G. J. A., Kang, M., Goggins, M., Yeo, C. J., Kern, S. E., & Hruban, R. H. (1998) · PubMed · Cited by 337
Self-citation(2001) · PubMed · Cited by 309
Self-citationImmunohistochemical Labeling for Dpc4 Mirrors Genetic Status in Pancreatic Adenocarcinomas
Wilentz, R. E., Su, G. H., Dai, J. L., Sparks, A. B., Argani, P., Sohn, T. A., Yeo, C. J., Kern, S. E., & Hruban, R. H. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64703-7 · Cited by 304
Self-citationMolecular prognostic markers in pancreatic cancer: A systematic review
Garcea, G., Neal, C. P., Pattenden, C. J., Steward, W. P., & Berry, D. P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.044 · Cited by 257
Villarroel, M. C., Rajeshkumar, N. V., Garrido‐Laguna, I., Jesus‐Acosta, A. D., Jones, S., Maitra, A., Hruban, R. H., Eshleman, J. R., Klein, A. P., Laheru, D. A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0893 · Cited by 249
Self-citationRecurrent KRAS codon 146 mutations in human colorectal cancer
Edkins, S., & O’Meara, S. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.3251 · Cited by 229
Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
Kojima, K., Vickers, S. M., Adsay, V. N., Jhala, N. C., Kim, H., Schoeb, T. R., Grizzle, W. E., & Klug, C. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4167 · Cited by 197
Mayo, S. C., Gilson, M. M., Herman, J. M., Cameron, J. L., Nathan, H., Edil, B. H., Choti, M. A., Schulick, R. D., Wolfgang, C. L., & Pawlik, T. M. (2011) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2011.09.022 · Cited by 176
Self-citationDPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma
Biankin, A. V., Morey, A. L., Lee, C.-S., Kench, J. G., Biankin, S. A., Hook, H. C., Head, D. R., Hugh, T. B., Sutherland, R. L., & Henshall, S. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.063 · Cited by 163
Balakrishnan, A., Bleeker, F. E., Lamba, S., Rodolfo, M., Daniotti, M., Scarpa, A., van Tilborg, A. A., Leenstra, S., Zanon, C., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0065 · Cited by 161
Iacobuzio–Donahue, C. A. (2011) · Gut · doi:10.1136/gut.2010.236026 · Cited by 158
Self-citationEmbuscado, E. E., Laheru, D. A., Ricci, F., Yun, K. J., Witzel, S. D. B., Seigel, A., Flickinger, K., Hidalgo, M. M., Bova, G. S., & Iacobuzio–Donahue, C. A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.5.1663 · Cited by 151
Self-citationMeta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
Smith, R. A., Tang, J. H., Smith, C. T., Neoptolemos, J. P., & Ghaneh, P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.110 · Cited by 109
Qiu, W., Sahin, F., Iacobuzio-Donahue, C. A., Garcia-Carracedo, D., Wang, W. M., Kuo, C.-Y., Chen, D., Arking, D. E., Lowy, A. M., Hruban, R. H., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.357 · Cited by 99
Self-citationIacobuzio–Donahue, C. A., Song, J., Parmiagiani, G., Yeo, C. J., Hruban, R. H., & Kern, S. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1121-3 · Cited by 93
Self-citationEvidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Fogelman, D. R., Wolff, R. A., Kopetz, S., Javle, M. M., Bradley, C. R., Mok, I., Cabanillas, F., & Abbruzzese, J. L. (2011) · PubMed · Cited by 91
Association of p53 Gene Mutations with Short Survival in Pancreatic Adenocarcinoma
Nakamori, S., Yashima, K., Murakami, Y., Ishikawa, O., Ohigashi, H., Imaoka, S., Yaegashi, S., Konishi, Y., & Sekiya, T. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb03036.x · Cited by 73
Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx
Obata, A., Eura, M., Sasaki, J., Saya, H., Chikamatsu, K., Tada, M., Iggo, R. D., & Yumoto, E. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000320)89:2 · Cited by 58
Geradts, J., Hruban, R. H., Schutte, M. E. M., Kern, S. E., & Maynard, R. D. (2000) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200003000-00011 · Cited by 56
Self-citationMelhem, M. F., Law, J. C., El-Ashmawy, L., Johnson, J. T., Landreneau, R. J., Srivastava, S., & Whiteside, T. L. (1995) · Europe PMC (PubMed Central) · Cited by 56
Šálek, C., Mináriková, P., Benešová, L., Nosek, V., Strnad, R., Zavoral, M., & Minárik, M. (2009) · PubMed · Cited by 33
Cited by
Sorted by citations
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Self-citationLaklai, H., Miroshnikova, Y. A., Pickup, M. W., Collisson, E. A., Kim, G., Barrett, A., Hill, R. C., Lakins, J. N., Schlaepfer, D. D., Mouw, J. K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4082 · Cited by 614
Self-citationPancreatic cancer biology and genetics from an evolutionary perspective
Makohon-Moore, A. P., & Iacobuzio–Donahue, C. A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.66 · Cited by 436
Self-citationMakohon-Moore, A. P., Zhang, M., Reiter, J. G., Bozic, I., Allen, B., Kundu, D., Chatterjee, K., Wong, F., Jiao, Y., Kohutek, Z. A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3764 · Cited by 403
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Metadata
- Authors
- Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., Hruban, R. H., Klein, A. P., Jones, S., Velculescu, V., Wolfgang, C. L., & Iacobuzio-Donahue, C. A.
- Affiliations
- Kurume University (JP)
- Authors' Affiliations: Departments of 1Pathology, 2Oncology, 3Surgery, and 4Radiation Oncology, The Sol Goldman Pancreatic Cancer Research Center, 5The Lugwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Medical Institutions, Baltimore, Maryland; 6National Cancer Center Research Institute, Tokyo; and 7Kurume University School of Medicine, Kurume, Fukuoka, Japan
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-11-14
- Volume
- 18
- Issue
- 22
- Pages
- 6339-6347
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3500447
- OpenAlex
- W2155563954
- Cited by
- 280
- References
- 43
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 17 · 2023: 22 · 2022: 27 · 2021: 33 · 2020: 25 · 2019: 15 · 2018: 20 · 2017: 23 · 2016: 15 · 2015: 22 · 2014: 15 · 2013: 12
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15)
- Japan Society for the Promotion of Science (23390326, 24659612)
- National Cancer Institute (CA-101955, P20CA101955, R01CA140599, P50CA101955, R01-CA121113, CA-121113, CA140599, P50CA062924, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, driver gene alterations, KRAS, CDKN2A, TP53, SMAD4, long-term survival, disease-free survival, metastatic burden, prognostic factors, autopsy tissue
- MeSH terms
- Aged, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Proto-Oncogene Proteins, Risk Factors, Proportional Hazards Models, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Survivors, Disease-Free Survival, ras Proteins, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Burden, Smad4 Protein, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
